PEA15 and ovarian carcinoma: In conclusion, non-phosphorylatable PEA-15AA increases cisplatin sensitivity of ovarian cancer cells, suggesting that the phosphorylation status of PEA-15 could be evaluated as a biomarker to predict the responsiveness of ovarian tumours to cisplatin treatment.